Merck: approval for triple-negative breast cancer drug
(CercleFinance.com) - Merck announced on Tuesday that the European Commission has approved its blockbuster immunotherapy Keytruda for the treatment of so-called "triple negative" breast cancer.
The US biopharmaceutical company said that Brussels has based its decision on the results of a Phase 3 clinical trial that showed the antibody, combined with chemotherapy, reduced the risk of death by 37% compared to chemotherapy alone.
The Commission's green light is for the post-operative treatment of adult patients with early or advanced triple-negative breast cancer, a type of cancer with a high risk of recurrence.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The US biopharmaceutical company said that Brussels has based its decision on the results of a Phase 3 clinical trial that showed the antibody, combined with chemotherapy, reduced the risk of death by 37% compared to chemotherapy alone.
The Commission's green light is for the post-operative treatment of adult patients with early or advanced triple-negative breast cancer, a type of cancer with a high risk of recurrence.
Copyright (c) 2022 CercleFinance.com. All rights reserved.